-1753896006195.webp&w=3840&q=75)
2025 NOSCM | Genomics in Treatment Decision for De Novo Acute Myeloid Leukemia
Overview
Dr. Fernandez discussed de novo AML, stressing fast diagnostics and ELN 2022 risk stratification. FLT3 mutations guide therapy; venetoclax+azacitidine boosts elderly outcomes. CPX-351 benefits high-risk patients over 60. MRD testing is key for treatment and transplant decisions, especially in youth.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Hugo F. Fernandez, MD
Date of Release
July 30th, 2025
-1753896080231.webp&w=3840&q=75)
-1753895830833.webp&w=3840&q=75)